Alvotech And Teva To Miss US Adalimumab Launch After Further FDA Setback

Firms Get Another CRL Over AVT02 High-Concentration Interchangeable Biosimilar

 
• By David Wallace
  
Red and blue wooden figures left out of larger group of yellow figures
Teva and Alvotech will not be able to join the group launching adalimumab biosimilars at the start of July • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products